2015/16 CSL Behring Facts
Sales $5.2 Billion
CSL Behring, a member of the CSL Group of companies, is a global biotherapeutics leader driven by our promise to save lives. Focused on serving patients’ needs by using the latest technologies, we develop and deliver innovative therapies to treat people with life-threatening medical conditions.
We collaborate with patient and biomedical communities to improve access to therapies, advance scientific knowledge, and support future medical research.
Our world-class commercial operation, combined with a large and focused R&D team and operational excellence, enable us to accurately identify, successfully develop, and dependably deliver innovations that patients and providers want.
CSL Behring operates one of the world’s largest plasma collection networks, CSL Plasma. The parent company, CSL Limited (ASX:CSL), is headquartered in Melbourne, Australia.
For more information visit www.cslbehring.com, and follow us on https://Twitter.com/CSLBehring
(@CSLBehring), Bio Blog http://blog.cslbehring.com, cslbehring.com/ and www.linkedin.com/company/csl-behring.
14,000+ employees worldwide
King of Prussia, Pennsylvania, USA
CSL Plasma is one of the world’s largest plasma collection organizations. The company operates more than 150 collection centers in the United States and Europe. Headquarters are in Boca Raton, Florida. Testing laboratories are located in the United States and Germany.
Bern, Switzerland; Marburg, Germany; Broadmeadows, Australia; and Kankakee, Illinois, USA
CSL integrated R&D includes facilities in Marburg, Germany; Bern, Switzerland; King of Prussia, Pennsylvania, USA; Kankakee, Illinois, USA; Tokyo, Japan; Broadmeadows and Parkville, Australia
Used for treatment of immunological disorders, such as primary immune deficiency, idiopathic thrombocytopenic purpura, Guillain-Barré syndrome and hemolytic disease of the newborn and to prevent cytomegalovirus infection in patients following solid organ transplant
Coagulation or bleeding disorders, including hemophilia and von Willebrand disease
Treatment of Alpha1-antitrypsin deficiency (hereditary emphysema), hereditary angioedema, and during surgery and for wound healing
Used for treatment of shock, burns and sepsis